Pfizer Inc. $PFE Shares Bought by Price T Rowe Associates Inc. MD

Key Points

• Price T Rowe Associates Inc. MD increased its holdings in Pfizer by 14.5% in Q1, now owning approximately 21.6 million shares valued at $547.7 million.
• Pfizer reported $0.78 earnings per share (EPS) for its most recent quarter, surpassing analyst expectations of $0.58, along with a revenue of $14.65 billion.
• The company declared a quarterly dividend of $0.43 per share, translating to an annual yield of 6.7%.

Price T Rowe Associates Inc. MD increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 14.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 21,615,496 shares of the biopharmaceutical company's stock after purchasing an additional 2,743,107 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.38% of Pfizer worth $547,737,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bessemer Group Inc. boosted its position in Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after buying an additional 13,228 shares during the period. Capital Advisors Inc. OK boosted its position in Pfizer by 1.2% in the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after buying an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp purchased a new position in Pfizer in the 1st quarter valued at approximately $8,283,000. Alta Advisers Ltd boosted its position in Pfizer by 69.6% in the 1st quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock valued at $809,000 after buying an additional 13,100 shares during the period. Finally, WCM Investment Management LLC boosted its position in Pfizer by 8.7% in the 1st quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock valued at $3,176,000 after buying an additional 10,051 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 2.8%

NYSE:PFE traded down $0.73 during midday trading on Monday, hitting $25.15. 32,304,503 shares of the company were exchanged, compared to its average volume of 45,249,543. The company has a fifty day simple moving average of $24.70 and a 200 day simple moving average of $24.39. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $142.99 billion, a PE ratio of 13.38, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the business earned $0.60 EPS. Pfizer's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analyst Weigh In

Several brokerages have commented on PFE. Redburn Atlantic decreased their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Wolfe Research raised their price objective on shares of Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. HSBC reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Finally, Bank of America raised their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.